Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Danish drug manufacturer Novo Nordisk is partnering with California-based biotech Septerna to develop the latest pills to ...

Novo Nordisk is moving forward with plans to develop oral obesity drugs through a new partnership, which comes as longtime CEO Lars Fruergaard Jørgensen prepares to step down. The drugmaker launched a ...

The U.S. Food and Drug Administration on Friday approved a new blood test for the early detection of Alzheimer's disease in ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...